细分来看，前三季度公司常规业务收入4亿元，同比增长12.32%；非常规业务收入4477.74万元，同比下降 59.76%。分季度来看，Q3公司实现营业收入1.59亿元，同比下降13.28%，其中常规业务收入1.36亿元，同比增长9.63%；非常规业务收入 1725.52万元，同比下降67.45%。①Affected by factors such as the decline in unconventional business income and fluctuations in cash management income, Yiqiao Shenzhou's third quarter revenue and net income attributable to the mother both declined; ② The increase in investment in CRO services and conventional reagents business led to a year-on-year increase in the company's cost of goods sold by more than 30%; ③ Yiqiao Shenzhou has repurchased the company's shares twice this year, with a total amount exceeding 0.4 billion yuan.
Caixin News Agency on October 22nd (Reporter He Fan) Affected by factors such as the decline in unconventional business income and fluctuations in cash management income, Yiqiao Shenzhou (301047.SZ) released a third quarter report tonight showing a decline in both revenue and net income attributable to the mother.
The financial report shows that the company achieved revenue of 0.465 billion yuan in the first three quarters of this year, a year-on-year decrease of 2.33%; the net profit attributable to the mother was 99.3153 million yuan, a year-on-year decrease of 51.6%.
Breaking it down, the company's regular business revenue in the first three quarters was 0.4 billion yuan, a year-on-year increase of 12.32%; unconventional business revenue was 44.7774 million yuan, a year-on-year decrease of 59.76%. Looking at the quarterly performance, in Q3, the company achieved revenue of 0.159 billion yuan, a year-on-year decrease of 13.28%, with regular business revenue at 0.136 billion yuan, a year-on-year increase of 9.63%; and unconventional business revenue at 17.2552 million yuan, a year-on-year decrease of 67.45%.
Regarding the reasons for the decline in performance, Yiqiao Shenzhou mentioned that it is mainly due to the decline in unconventional business income, fluctuations in cash management income, and the fact that the Suzhou subsidiary and the Center for Biological Engineering (C4B) are still in the early stage of business expansion, unable to cover operating costs temporarily.
In fact, the company's unconventional business income has been dragging down performance this year. Looking at the first quarter and semi-annual reports, the revenue of this sector has decreased by 68.88% and 52.76% year-on-year respectively.
At the same time, due to increased investment in CRO services and conventional reagents business, Yiqiao Shenzhou's cost of goods sold has risen to 0.119 billion yuan, an increase of 33.37% year-on-year.
It is worth noting that Yiqiao Shenzhou has repurchased company shares twice this year. On February 22nd, using its own funds, the company implemented the first repurchase through a centralized bidding trading method via a share repurchase special securities account. As of July 5th, the company had repurchased 3.0294 million shares, accounting for 2.34% of the total share capital before cancellation. The highest fill price was 74.67 yuan/share, the lowest fill price was 58.50 yuan/share, with a total fill amount of 0.2 billion yuan (excluding transaction costs). The share repurchase plan has been completed, and the share repurchase cancellation matter was completed on July 12th.
On August 1, Yiqiao Shenzhou once again announced that it plans to use 0.2 billion-0.4 billion of its own funds to repurchase shares through centralized competitive bidding, with a repurchase price not exceeding 90 yuan/share. As of September 30, the company has repurchased a total of 4.5339 million shares at a fill price between 53.55/share and 58.70/share, accounting for 3.59% of the company's total share capital. The total transaction amount is 0.253 billion yuan (excluding transaction costs).
On the other hand, the repurchase of shares has led to a decrease in the company's mmf. As of the end of this reporting period, Yiqiao Shenzhou's mmf is 0.889 billion yuan, a decrease of 32.46% compared to the end of the previous year.
